{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:50:27Z","timestamp":1790351427177,"version":"4.1.0"},"reference-count":81,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Chem Biol Drug Des"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>BCR\u2010ABL is a gene produced by the fusion of the bcr gene and the c\u2010abl proto\u2010oncogene and is considered to be the main cause of chronic myelogenous leukemia (CML) production. Therefore, the development of selective Bcr\u2010Abl kinase inhibitors is an attractive strategy for the treatment of CML. However, in the treatment of CML with a <jats:italic>Bcr\u2010Abl<\/jats:italic> kinase inhibitor, the T315I gatekeeper mutant disrupts the important contact interaction between the inhibitor and the enzyme, resistant to the first\u2010 and second\u2010generation drugs currently approved, such as imatinib, bosutinib, nilotinib, and dasatinib. In order to overcome this special resistance, several different strategies have been explored, and many molecules have been studied to effectively inhibit <jats:italic>Bcr\u2010Abl<\/jats:italic> T315I. Some of these molecules are still under development, and some are being studied preclinically, and still others are in clinical research. Herein, this review reports some of the major examples of third\u2010generation <jats:italic>Bcr\u2010Abl<\/jats:italic> inhibitors against the T315I mutation.<\/jats:p>","DOI":"10.1111\/cbdd.13801","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T08:22:32Z","timestamp":1602231752000},"page":"649-664","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Recent advances in Bcr\u2010Abl tyrosine kinase inhibitors for overriding T315I mutation"],"prefix":"10.1111","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-9996","authenticated-orcid":false,"given":"Juan","family":"Liu","sequence":"first","affiliation":[{"name":"Institute of Pharmacy and Pharmacology Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study University of South China Hengyang China"},{"name":"Pharmacy Department of Yiyang Central Hospital Yiyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy and Pharmacology Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study University of South China Hengyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Huang","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy and Pharmacology Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study University of South China Hengyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Lei","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy and Pharmacology Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study University of South China Hengyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guotao","family":"Tang","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy and Pharmacology Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study University of South China Hengyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Cao","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy and Pharmacology Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study University of South China Hengyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmei","family":"Peng","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy and Pharmacology Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study University of South China Hengyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio760"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200319"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0117"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.08.006"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.08.009"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0102250"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.08.048"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.03.003"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2012.06.036"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0741-6"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.26686"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3097"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.2.690"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3224"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.03.067"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-29"},{"issue":"1","key":"e_1_2_8_19_1","first-page":"1","article-title":"Past, present, and future of bcr\u2010abl inhibitors: From chemical development to clinical efficacy","volume":"11","author":"Federico R.","year":"2018","journal-title":"Journal of Hematology & Oncology"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(03)00979-3"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168146"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.156"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm301891t"},{"issue":"15","key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1158\/1538-7445.AM2015-5389","article-title":"Abstract 5389: novel kinase inhibitor for imatinib\u2010resistant chronic myeloid leukemia with t315i mutation","volume":"75","author":"Hong S. S.","year":"2015","journal-title":"Cancer Research"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800984v"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100395q"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01040"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1358"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14683"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2837"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.10.007"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio799"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0896(98)00099-6"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986711795656135"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2016.1250757"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0805-1"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.07.116"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.07.230"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M605902200"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.04.056"},{"key":"e_1_2_8_42_1","first-page":"4236","article-title":"Crystal structures of the kinase domain of c\u2010abl in complex with the small molecule inhibitors pd173955 and imatinib (sti\u2010571)","volume":"62","author":"Nagar B.","year":"2002","journal-title":"Cancer Research"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411016"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.064618"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25551"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.2174\/156802608784911635"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3314"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-066936"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206094"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201100410"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14119"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0101"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1199"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26324"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2324"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-419X(97)00023-1"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm4004076"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986710790936310"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1036259"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12183"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389557518666181017124854"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314712110"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1516"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.05.007"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-211466"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25092"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-251751"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2126"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21702"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.10023"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm4003928"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0713356"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10881"},{"key":"e_1_2_8_75_1","first-page":"721","article-title":"Research progress of small molecular bcr\u2010abl inhibitors for the treatment of ph~+ leukemia","volume":"10","author":"Ying\u2010Hong Z.","year":"2011","journal-title":"Chinese Journal of Antibiotics"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.03.012"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08675"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.02.017"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.67"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2010.01054.x"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2007.00556.x"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4827(80)90279-7"}],"container-title":["Chemical Biology &amp; Drug Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cbdd.13801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cbdd.13801","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cbdd.13801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T16:02:35Z","timestamp":1693670555000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cbdd.13801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/cbdd.13801"],"URL":"https:\/\/doi.org\/10.1111\/cbdd.13801","archive":["Portico"],"relation":{},"ISSN":["1747-0277","1747-0285"],"issn-type":[{"value":"1747-0277","type":"print"},{"value":"1747-0285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"2020-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}